On November 1, 2024, the R-Pharm Group of Companies launched clinical trials to assess the bioequivalence of their generic version of AbbVie’s “Mavyret” (glecaprevir + pibrentasvir), a medication utilized for the treatment of hepatitis C across all genotypes. This follows from the data of the state register of medicines. The trials, which will be held on the basis of one medical organization – Research Lab LLC, will involve 165 volunteers. The clinical trials are expected to conclude by the end of 2027.
The original “Mavyret,” a highly effective but costly treatment for hepatitis C, is provided to the Russian market by American pharmaceutical giant AbbVie, with local partner R-Pharm handling its packaging. The maximum registered price for a package of 84 tablets of “Mavyret,” sufficient for a four-week course of treatment, is set at 171,700 rubles. The full course of treatment, depending on the genotype and the presence of cirrhosis, can be 8 or 12 weeks.
